Health Care & Life Sciences » Biotechnology | Northwest Biotherapeutics Inc.

Northwest Biotherapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
809.00
1,454.00
1,739.00
623.00
336.00
412
SG&A Expense
56,270.00
102,586.00
127,967.00
79,700.00
54,575.00
39,365
EBIT
55,473.00
101,143.00
126,284.00
79,266.00
54,678.00
40,253
Unusual Expense
9,442.00
33,518.00
15,676.00
9,602.00
17,444.00
13,884
Non Operating Income/Expense
1.00
23.00
20.00
6,732.00
4,524.00
446
Interest Expense
873.00
996.00
4,153.00
3,818.00
5,545.00
9,871
Pretax Income
65,789.00
135,634.00
114,741.00
80,214.00
73,143.00
35,794
Consolidated Net Income
65,789.00
135,634.00
114,741.00
85,861.00
73,143.00
35,794
Net Income
65,789.00
135,634.00
114,741.00
85,861.00
73,143.00
35,794
Net Income After Extraordinaries
65,789.00
135,634.00
114,741.00
85,861.00
73,143.00
35,794
Net Income Available to Common
65,789.00
135,634.00
114,741.00
85,861.00
74,409.00
53,559
EPS (Basic)
2.00
2.29
1.48
0.77
0.31
0.12
Basic Shares Outstanding
32,865.00
59,248.00
77,713.00
111,078.00
242,849.00
440,016
EPS (Diluted)
2.00
2.29
1.48
0.77
0.31
0.12
Diluted Shares Outstanding
32,865.00
59,248.00
77,713.00
111,078.00
242,849.00
440,016
EBITDA
55,461.00
101,132.00
126,228.00
79,077.00
54,239.00
38,953
Other After Tax Income (Expense)
-
-
-
5,647.00
-
-
Preferred Dividends
-
-
-
-
1,266.00
17,765

About Northwest Biotherapeutics

View Profile
Address
4800 Montgomery Lane
Bethesda Maryland 20814
United States
Employees -
Website http://www.nwbio.com
Updated 07/08/2019
Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. The firm engages in the development of cancer vaccines designed to treat solid tumor cancers. It also offers a platform technology for DCVax dendritic cell-based vaccines.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.